Opinion

Video

Common Adverse Reactions to EGFR Therapy

Alan Chin, PharmD, BCOP, presents an overview of the most prevalent and common adverse reactions associated with EGFR-targeted therapies in metastatic NSCLC and shares strategies to mitigate toxicities, with a focus on managing dermatologic events such as rash and itching.

  1. Provide a broad overview of common adverse effects associated with EGFR-targeted therapies in metastatic NSCLC.
  2. What proactive strategies do you recommend for preventing dermatologic toxicities, such as rash and acneiform eruptions, in patients receiving EGFR-targeted therapies?
Related Videos
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
4 experts are featured in this series.
4 experts are featured in this series.
5 experts in this video
5 experts in this video
5 experts in this video
4 experts are featured in this series.
Related Content
Phogomicrograph of fine needle aspiration (FNA) cytology of a pulmonary (lung) nodule showing adenocarcinoma, a type of non small cell carcinoma.
February 20th 2025

FDA Grants Priority Review to Zongertinib for Treatment of HER2-Mutated, Advanced Non-Small Cell Lung Cancer

Luke Halpern, Assistant Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

Tumor in lungs -- Image credit: Sebastian Kaulitzki | stock.adobe.com
February 16th 2025

Targeting DLL3 in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Aubrey R. Lasko, PharmD, BCOP Catherine B. Meador, MD, PhD
Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment
June 27th 2024

Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment

AI illustration of targeted therapies attacking cancer cells | Image Credit: © Wanlop - stock.adobe.com
February 13th 2025

Real-World Study Shows Efficacy, Safety of First-Line Dacomitinib in Patients With EGFR-Mutated NSCLC

Alexandra Gerlach, Associate Editor
Woman stepping on a scale
February 5th 2025

Obesity in Patients With Non-Small Cell Lung Cancer Is Linked to Longer Survival

Alexandra Gerlach, Associate Editor